Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Q-Line Biotech share price today

QLINETrading companyConsolidatedPrices to 20 Nov 2026Results to Sep 2026

10Y not available: listed May 2026
Price, 200-day average and NIFTY 500Since May 2026Since May 2026

The price is 26.9% below its 200-day average and 22 points behind the NIFTY 500 since listing in May 2026

20 Nov 2026₹396.80Since listing in May 2026: Q-Line Biotech −16.4%, NIFTY 500 +5.5%
₹400₹600Aug 26Nov 26

Price growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

EPS and P/ESince May 2026Since May 2026

EPS for the last four quarters not in our data, no figure to compare; no P/E

20 Nov 2026Not in our dataNo P/E on 20 Nov 2026: earnings for the last four quarters are not in our data
Sep 26
₹0

EPS growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

Revenue and marginsSince May 2026Insufficient history, from Mar 2023

Revenue up on a year; operating margin 26.3%

Sep 2026 quarter₹152 crore+5.6% on ₹144 crore a year earlier · NPM 13.2%
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹250

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+9.3% to Mar3Y+23.2%/yr to Mar
Rev 5Y, Rev growth10YToo short
OPM average3Y24.1% to Mar5YToo short
NPM average3Y12.7% to Mar5YToo short

Return on capitalInsufficient history, from Mar 2024Insufficient history, from Mar 2024

ROCE was 22.2% for the year to Mar 2026, up from 16.1% in the year to Mar 2024

Year to Mar 202622.2% ROCEInsufficient history: data from Mar 2024
15%20%Sep 24Mar 25Sep 25Mar 26

ROCE average

1Y3Y5Y10Y1Y22.2% to Mar3Y20.8% to Mar5YToo short10YToo short

Profit and cashInsufficient history, from Mar 2023Insufficient history, from Mar 2023

Cash from operations was 24% of profit over 4 years, 29% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹16 crore operating cashProfit ₹56 crore · Free cash −₹20 crore
FY23
FY24
FY25
FY26
₹75−₹75

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+194.7% to Mar3Y+20.5%/yr to Mar5YToo short10YToo short

ReinvestmentInsufficient history, from Mar 2023Insufficient history, from Mar 2023

Capex was ₹36 crore in the year to Mar 2026, 3.3 times depreciation

FY26₹36 crore capexWork in progress ₹19 crore
FY23
FY24
FY25
FY26
0₹75

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−48.8% to Mar3Y+6.6%/yr to Mar5YToo short10YToo short

BorrowingsSince May 2026Since May 2026

Debt ÷ equity 0.27 at 30 Sep 2026; profit covered interest 4.2x over the last four quarters

Sep 2026 balance sheet0.27 debt ÷ equityNet cash ₹54 crore
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
06x

Safety

Now3Y ago
Debt ÷ equity0.273Y agon/a
Int. cover4.2x3Y ago8.5x

Operating healthSince May 2026Since May 2026

Working capital rose from -44 to 62 days since FY23

Year to Mar 202662 days working capital
-50100Mar 24Mar 25Mar 26
Working cap.621Y+173Y+1065YToo short
Debtor1341Y+383Y+685YToo short
Inventory2581Y+333Y+785YToo short

OwnershipInsufficient history, from Sep 2026Insufficient history, from Sep 2026

FIIs own 0.88%; no figure a year earlier. Promoters hold 67.51%

Share of the company held, %, by quarter end

Sep 2026 quarter0.88% FIIsNo figure a year earlier
0%50%

FIIs 1Y, FIIs 3Y, Promoters 1Y, Promoters

3Y3YToo short

Q-Line Biotech Ltd · QLINE · Trading · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 13 November 2026

Q-Line Biotech share price today: ₹396.80 at the close on 20 November 2026. Q-Line Biotech (QLINE) is worth ₹926 crore and trades at a P/E of 16.9.

₹396.80Price
16.9×P/E lower than 100% of the last 6 months
₹152 CrRevenue (Sep 2026) +5.6% on a year ago
₹20.0 CrProfit (Sep 2026) −4.8% on a year ago
26.3%Operating margin +1.3 points on a year ago
22.2%ROCE year to Mar 2026

Q-Line Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.

Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business.

The price is in an uptrend that has just slipped below its 200-day average, and the P/E is lower than 100% of its own last 6 months. Over the last four quarters, results have been mixed, with profit −4.8% on a year earlier, and 8% of the last 3 years' profit came in as cash. What will decide it: the next one or two quarters of results.

Left out of this page: Its two data sources disagree by up to 49% on reported income across 2 comparable periods, so nothing from the second source is shown here. That is why the yearly return-on-capital-used (ROIC) line and the F-score, the Z-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Q-Line Biotech share price today?

Q-Line Biotech Ltd's share price was ₹396.80 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 26.9% below its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Q-Line Biotech Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 12 June 2026, it has traded between ₹397 and ₹726, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 9 of 13 weeks

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
12 Jun 2026no NIFTY 500 reading
19 Jun 2026no NIFTY 500 reading
25 Jun 2026no NIFTY 500 reading
3 Jul 2026no NIFTY 500 reading
10 Jul 2026no NIFTY 500 reading
17 Jul 2026no NIFTY 500 reading
24 Jul 2026no NIFTY 500 reading
31 Jul 2026no NIFTY 500 reading
7 Aug 2026no NIFTY 500 reading
14 Aug 2026no NIFTY 500 reading
21 Aug 2026no NIFTY 500 reading
28 Aug 2026no NIFTY 500 reading
4 Sep 2026no NIFTY 500 reading
11 Sep 2026+41.4%
18 Sep 2026+25.2%
25 Sep 2026+24.5%
28 Sep 2026+20.4%
1 Oct 2026+26.8%
9 Oct 2026+24.6%
16 Oct 2026+27.1%
23 Oct 2026+6.5%
30 Oct 2026+2.8%
6 Nov 2026−3.4%
8 Nov 2026−3.9%
13 Nov 2026−11.9%
20 Nov 2026−40.0%
Each bar is one week, from 2026 to now (13 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 5 months the share price moved −22% while the NIFTY 500 moved +5%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What are Q-Line Biotech's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Q-Line Biotech reported revenue of ₹152 crore, up 5.6% from ₹144 crore a year earlier, and a profit of ₹20.0 crore, down 4.8% from ₹21.0 crore.

Q-Line Biotech results: July to September 2026 against a year earlier

Q-Line Biotech results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹152 crore₹144 crore+5.6%
Profit₹20.0 crore₹21.0 crore−4.8%
Earnings per share₹8.40₹13.10−35.9%
Operating margin26.3%25.0%+1.3 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Q-Line Biotech's management discussed these results on a call held on 13 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Q-Line Biotech share price history?

Q-Line Biotech closed at ₹396.80 on 20 November 2026. Its highest weekly close since June 2026 was ₹726.20 on 11 September 2026.

Q-Line Biotech share price: then and now

Q-Line Biotech share price: then and now
WhenCloseChange to 20 Nov 2026
1 week ago · 13 Nov 2026₹488.30−18.7%
1 month ago · 19 Oct 2026₹600.55−33.9%
Earliest weekly close in our records · 12 Jun 2026₹509.30−22.1%
Highest weekly close since June 2026 · 11 Sep 2026₹726.20−45.4%
Lowest weekly close since June 2026 · 20 Nov 2026₹396.800.0%

Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

26 weekly closes from 12 June 2026 to 20 November 2026.

What is the latest news on Q-Line Biotech?

20 Nov 2026: Q-Line Biotech closed at ₹396.80, down 18.7% on the week and down 33.9% on the month. 13 Nov 2026: Q-Line Biotech held its results call for July to September 2026. Management guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO.

Earlier

  • Results for July to September 2026: Revenue up 5.6% and profit down 4.8% on a year earlier.

What dividend does Q-Line Biotech pay?

Q-Line Biotech has paid no dividend on the exchange since its first close in our records (12 June 2026), the start of the period we checked.

No. Q-Line Biotech Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 20 November 2026.

What did Q-Line Biotech management say on the latest results call?

On the call for July to September 2026, held on 13 November 2026, Q-Line Biotech's management guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO.

“Therefore, we are very confident about the 400 crore number. There is no doubt about it.”Ajay Kumar Mohanty, on the call for July to September 2026

What management guided

  • Steady-state operating profit 28% for FY27 with profit 15-16% as H2 interest savings ₹4-5 crore offsets Unit-4 depreciation.
  • Unit-4 operations H2FY27 at 25-30% capacity, ₹150-160 crore FY27 and ₹250 crore FY28, ₹120 crore minimum up to ₹250-300 crore on Class C/D.
  • Heidelco FY27 revenue around ₹130 crore on critical-care scale and synergies.
  • Chemiluminescence January to March 2027, Q-Count autoloader November and Hb meter invoices month-end on NODs.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 13 November 2026.

What to watch in Q-Line Biotech's next results?

When Q-Line Biotech reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Pending government instrument orders converting once consignee lists arrive - delivery in H2 print versus further deferral.

Management raised each of these on the latest results call.

  • Pending government instrument orders converting once consignee lists arrive - delivery in H2 print versus further deferral.
  • Unit-4 progressing to full H2 operations on pending licences - licence build and kit output versus slip.
  • European principal CDMO order shipping with follow-on volumes - dispatch and reorder versus one-off in coming quarters.
  • Heidelco stake closing and consolidation - shareholder approval and SPA terms versus lapse in next quarter.

Which stock lists is Q-Line Biotech on?

Q-Line Biotech is not on any of our India lists this week.

Is Q-Line Biotech profitable?

Q-Line Biotech Ltd earned ₹20.0 Cr of net profit in the Sep 2026 quarter, −4.8% on the same quarter a year earlier. Full-year FY26 profit was ₹56.0 Cr. Over 3 years profit has grown 20.5% a year on average. The Sep 2026 quarter's profit is 13.2% of that quarter's revenue. The same quarter a year earlier earned ₹0.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹56.0 Cr (+194.7% on the year before).

How much revenue does Q-Line Biotech make, and is it growing?

Q-Line Biotech Ltd reported ₹152 Cr of revenue in the Sep 2026 quarter, +5.6% on the same quarter a year earlier. Over 3 years it has grown 23.2% a year on average. The last full year, FY26, came in at ₹342 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹342 Cr, +9.3% on the year before.

Recent pace: the last four quarters grew −1.6% on average, against 23.2% a year over the longer run, so this year is growing slower than its own long-run rate.

How much of every ₹100 of sales does Q-Line Biotech keep?

Q-Line Biotech Ltd's operating margin was 26.3% in the Sep 2026 quarter, 1.3 percentage points higher than the same quarter a year ago. Across 4 years it has been between 18.6% and 28.7%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason.

Is Q-Line Biotech's profit turning into cash?

Over the last 3 years, 8% of Q-Line Biotech Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹16.0 Cr of operating cash against ₹56.0 Cr of profit. After ₹36.0 Cr of spending on assets, free cash was −₹20.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 8% of profit came in as cash: the cash cycle got 169 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 169 days longer. The next section looks at where the cash is stuck.

Where does Q-Line Biotech's cash go?

Q-Line Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 251 days in FY26, up from 82 days in FY23. It spent ₹155 Cr on assets over the last 3 years. Customers take 134 days to pay, and stock sits for 258 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹342 Cr, each day of that cycle ties up about ₹0.9 Cr, so roughly ₹235 Cr is tied up in the business at any time.

FY26: customers took 134 days to pay and stock sat for 258 days, about 8.5 months of sales sitting as stock, for a full cycle of 251 days, longer than FY23's 82.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 258 days. Customers pay about 134 days after that. Suppliers are paid at 142 days. Together that makes the 251-day cycle.

Spending on assets: ₹155 Cr over the last 3 years, against ₹22.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹19.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

What is Q-Line Biotech's P/E ratio, and how does it compare with its own history?

Q-Line Biotech Ltd's P/E is 16.9×, about the lowest it has ever been. Its usual P/E (the middle reading) is 22.8×, over 6 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

16.9×P/E · lower than 100% of its last 6 months

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Is the Q-Line Biotech business getting better or worse?

Q-Line Biotech Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highROCE · latest (year to Mar 2026) 22.2%, range 16.0% to 24.0%

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+9.3%+23.2%——
Profit+194.7%+20.5%——
EPS+181.6%+19.0%——
+5.6%Revenue growth (Sep 2026) · latest quarter against a year ago
−4.8%Profit growth (Sep 2026) · latest quarter against a year ago
23.2%Revenue, 3 years · yearly growth over the long run

How much does Q-Line Biotech earn on its capital?

Q-Line Biotech Ltd earned a ROCE of 22% in FY26. That is up from a low of 16% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 16.4% net margin and 0.61× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 16.4% net margin × 0.61× asset turnover × 2.27× leverage (assets divided by equity) ≈ 22.7% on equity. The margin does most of the work; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 49% on reported income across 2 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Does Q-Line Biotech have too much debt?

Q-Line Biotech Ltd had ₹225 Cr of borrowings against ₹246 Cr of equity in FY26, so its debt is 0.91× its equity. Its operating profit is 5 times its interest bill. Over 3 years borrowings went from ₹74.0 Cr to ₹225 Cr. Over the last 3 of those years it spent ₹155 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

What is the Q-Line Biotech shareholding pattern?

No group of Q-Line Biotech Ltd's owners changed its stake by a full percentage point over the last 2 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

How far is Q-Line Biotech from balance-sheet trouble?

For Q-Line Biotech Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

How does Q-Line Biotech rank in its industry?

59.9 out of 100, rank 48 of 65 in Trading, with 31% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Q-Line Biotech Ltd scores 59.9 out of 100 against the 65 companies it is compared with in Trading, ranking 48. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 21.8 + 24.9 + 13.2 = 59.9 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Q-Line Biotech compared with?

Q-Line Biotech ranks 48 of 65 Trading companies on the 4-Factor Sector Score, with 59.9 out of 100.

  1. 1Shankara Buildpro LtdBUILDPRO · quiet · Most evidence points up · 63% evidence68.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 31.4/43.75 · Revenue 30.2% · Profit 38% · Operating margin change 0.3 points · 100% evidenceCapital efficiency 23.2/31.25 · ROCE 39% (year to Mar 2026) · Operating margin 3.4% · 100% evidenceValuation 13.4/25 · P/E 15.2× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 31.4 + 23.2 + 13.4 = 68 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  2. 2Mangalam Global Enterprise LtdMGEL · breaking out · Most evidence points up · 83% evidence65.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.4/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidenceCapital efficiency 14.8/25 · ROCE 17% (year to Mar 2026) · Operating margin 2.3% · 100% evidenceValuation 10.8/20 · P/E 15.1× · PEG — · 15% evidenceRelative strength 17.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.6% · Strength vs NIFTY 500 (same reading) 19.3% · 1 year 19% · 100% evidence · 5 of 12 weeks aheadExact sum: 22.4 + 14.8 + 10.8 + 17.9 = 65.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3Nupur Recyclers LtdNRL · leader · Most evidence points up · 82% evidence65.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.0/35 · Revenue 79.3% · Profit 71.5% · Operating margin change 2.9 points · 95% evidenceCapital efficiency 15.0/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 9.9% · 76% evidenceValuation 7.8/20 · P/E 59.7× · PEG — · 50% evidenceRelative strength 19.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 76.1% · Strength vs NIFTY 500 (same reading) 90.2% · 1 year 196.2% · 100% evidence · 12 of 12 weeks aheadExact sum: 23 + 15 + 7.8 + 19.7 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Rashi Peripherals LtdRPTECH · losing its lead · Evidence leans up · 82% evidence64.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.0/35 · Revenue 51.1% · Profit 93.2% · Operating margin change 1.1 points · 95% evidenceCapital efficiency 15.1/25 · ROCE 17% (year to Mar 2026) · Operating margin 3.6% · 76% evidenceValuation 10.8/20 · P/E 11.1× · PEG — · 50% evidenceRelative strength 11.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.2% · Strength vs NIFTY 500 (same reading) 15.3% · 1 year 98% · 100% evidence · 9 of 12 weeks aheadExact sum: 27 + 15.1 + 10.8 + 11.7 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Bhatia Communications & Retail (India) Ltdturning · Evidence leans up · 72% evidence63.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.9/35 · Revenue 55.2% · Profit 72.1% · Operating margin change 1.5 points · 95% evidenceCapital efficiency 18.6/25 · ROCE 21.3% (year to Mar 2026) · Operating margin 5.7% · 95% evidenceValuation 9.3/20 · P/E 25.1× · PEG — · 50% evidenceRelative strength 11.8/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 39.8% · 1 year — · 25% evidence · 1 of 1 week aheadExact sum: 23.9 + 18.6 + 9.3 + 11.8 = 63.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  6. 6Maxgrow India Ltdturning · Too little evidence to rank firmly · 57% evidence63.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.6/35 · Revenue 100% · Profit 100% · Operating margin change -0.2 points · 71% evidenceCapital efficiency 16.2/25 · ROCE 23.5% (year to Mar 2026) · Operating margin 1.6% · 95% evidenceValuation 11.4/20 · P/E 1.1× · PEG — · 15% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 100.1% · 1 year — · 25% evidence · 1 of 1 week aheadExact sum: 23.6 + 16.2 + 11.4 + 12.3 = 63.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  7. 7Arisinfra Solutions LtdARIS · breaking out · Evidence leans up · 60% evidence63.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.7/35 · Revenue 41.7% · Profit 100% · Operating margin change 3 points · 95% evidenceCapital efficiency 13.8/25 · ROCE 15.6% (year to Mar 2026) · Operating margin 11.7% · 76% evidenceValuation 10.4/20 · P/E 18.5× · PEG — · 15% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 13.6% · 1 year 8.9% · 25% evidence · 11 of 12 weeks aheadExact sum: 27.7 + 13.8 + 10.4 + 11.2 = 63.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Dhunseri Ventures LtdDVL · breaking out · Evidence leans up · 74% evidence61.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.8/35 · Revenue 21.4% · Profit 100% · Operating margin change 82 points · 71% evidenceCapital efficiency 11.1/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 12.8/20 · P/E 3.5× · PEG — · 50% evidenceRelative strength 15.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 14.8% · 1 year 3.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.8 + 11.1 + 12.8 + 15.6 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9SG Mart LtdSGMART · leader · Evidence leans up · 83% evidence61.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.0/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidenceCapital efficiency 11.6/25 · ROCE 10.2% (year to Mar 2026) · Operating margin 4.6% · 100% evidenceValuation 9.2/20 · P/E 91.1× · PEG — · 15% evidenceRelative strength 18.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 43.2% · Strength vs NIFTY 500 (same reading) 56.8% · 1 year 214.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 22 + 11.6 + 9.2 + 18.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10DC Infotech & Communication LtdDCI · quiet · Evidence leans up · 75% evidence60.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.9/35 · Revenue 33.9% · Profit 37.6% · Operating margin change -0.3 points · 100% evidenceCapital efficiency 16.6/25 · ROCE 23% (year to Mar 2026) · Operating margin 5.2% · 100% evidenceValuation 10.1/20 · P/E 26.9× · PEG — · 50% evidenceRelative strength 11.1/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 12.1% · 1 year — · 25% evidence · 6 of 8 weeks aheadExact sum: 22.9 + 16.6 + 10.1 + 11.1 = 60.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  11. 11Singer India LtdSINGERIND · breaking out · Evidence leans up · 68% evidence60.0out of 100GrowthCapitalValuationRelative
  12. 12Ivalue Infosolutions LtdIVALUE · quiet · Evidence leans up · 78% evidence58.3out of 100GrowthCapitalValuationRelative
  13. 13Aayush Art and Bullion Ltdleader · Too little evidence to rank firmly · 59% evidence58.0out of 100GrowthCapitalValuationRelative
  14. 14Vision Infra Equipment Solutions LtdVIESL · losing its lead · Too little evidence to rank firmly · 60% evidence57.6out of 100GrowthCapitalValuationRelative
  15. 15Patel Retail LtdPATELRMART · breaking out · Evidence leans up · 68% evidence57.4out of 100GrowthCapitalValuationRelative
  16. 16Tembo Global Industries LtdTEMBO · quiet · Evidence leans up · 71% evidence57.2out of 100GrowthCapitalValuationRelative
  17. 17Euro Pratik Sales LtdEUROPRATIK · basing · Evidence leans up · 68% evidence55.2out of 100GrowthCapitalValuationRelative
  18. 18Prostarm Info Systems LtdPROSTARM · quiet · Evidence leans up · 68% evidence54.7out of 100GrowthCapitalValuationRelative
  19. 19Mardia Samyoung Capillary Tubes Company LtdMSCTC · Evidence leans up · 60% evidence52.5out of 100GrowthCapitalValuationRelative
  20. 20BMW Ventures LtdBMW · breaking out · Evidence leans up · 60% evidence51.7out of 100GrowthCapitalValuationRelative
  21. 21MMTC LtdMMTC · quiet · Evidence leans up · 86% evidence50.9out of 100GrowthCapitalValuationRelative
  22. 22Transchem LtdTRANSCHEM · turning · Evidence leans up · 60% evidence50.7out of 100GrowthCapitalValuationRelative
  23. 23Shiv Aum Steels LtdSHIVAUM · breaking out · Evidence leans up · 67% evidence50.5out of 100GrowthCapitalValuationRelative
  24. 24Cropster Agro LtdCROPSTER · Evidence leans down · 60% evidence49.6out of 100GrowthCapitalValuationRelative
  25. 25Sudarshan Pharma Industries Ltdquiet · Evidence leans down · 87% evidence48.9out of 100GrowthCapitalValuationRelative
  26. 26Hexa Tradex LtdHEXATRADEX · quiet · Evidence leans down · 74% evidence44.9out of 100GrowthCapitalValuationRelative
  27. 27Adani Enterprises LtdADANIENT · quiet · Evidence leans down · 93% evidence44.4out of 100GrowthCapitalValuationRelative
  28. 28A-1 LtdA1L · Evidence leans down · 60% evidence43.5out of 100GrowthCapitalValuationRelative
  29. 29Blue Pearl Agriventures LtdBPAGRI · basing · Too little evidence to rank firmly · 57% evidence43.1out of 100GrowthCapitalValuationRelative
  30. 30Lloyds Enterprises LtdLLOYDSENT · quiet · Evidence leans down · 75% evidence40.9out of 100GrowthCapitalValuationRelative
  31. 31Shanti Overseas (India) LtdSHANTI · Evidence leans down · 61% evidence39.0out of 100GrowthCapitalValuationRelative
  32. 32Riddhi Siddhi Gluco Biols Ltdquiet · Evidence leans down · 87% evidence37.4out of 100GrowthCapitalValuationRelative
  33. 33Fabtech Technologies LtdFABTECH · basing · Evidence leans down · 68% evidence37.0out of 100GrowthCapitalValuationRelative
  34. 34PTC India LtdPTC · quiet · Evidence leans down · 82% evidence35.8out of 100GrowthCapitalValuationRelative
  35. 35Uniphos Enterprises LtdUNIENTER · basing · Evidence leans down · 75% evidence35.8out of 100GrowthCapitalValuationRelative
  36. 36Hardwyn India LtdHARDWYN · quiet · Evidence leans down · 90% evidence35.7out of 100GrowthCapitalValuationRelative
  37. 37Shah Foods Ltdquiet · Too little evidence to rank firmly · 53% evidence34.5out of 100GrowthCapitalValuationRelative
  38. 38Manbro Industries LtdToo little evidence to rank firmly · 52% evidence33.4out of 100GrowthCapitalValuationRelative
  39. 39BN Agrochem LtdBNAGROCHEM · basing · Most evidence points down · 64% evidence33.2out of 100GrowthCapitalValuationRelative
  40. 40Kothari Industrial Corporation LtdKOTIC · quiet · Too little evidence to rank firmly · 53% evidence33.2out of 100GrowthCapitalValuationRelative
  41. 41Neueon Corporation LtdNEUEON · quiet · Too little evidence to rank firmly · 56% evidence32.1out of 100GrowthCapitalValuationRelative
  42. 42Oswal Agro Mills LtdOSWALAGRO · basing · Most evidence points down · 60% evidence30.6out of 100GrowthCapitalValuationRelative
  43. 43Le Merite Exports LtdLEMERITE · Too little evidence to rank firmly · 58% evidence26.5out of 100GrowthCapitalValuationRelative
  44. 44Yogi LtdYOGI · turning · Most evidence points down · 70% evidence24.9out of 100GrowthCapitalValuationRelative
  45. 45Pervasive Commodities Ltdbreaking out · Too little evidence to rank firmly · 47% evidence64.5out of 100GrowthCapitalValuationRelative
  46. 46Magnus Steel & Infra LtdToo little evidence to rank firmly · 40% evidence61.1out of 100GrowthCapitalValuationRelative
  47. 47Susan Electricals India LtdToo little evidence to rank firmly · 36% evidence59.9out of 100GrowthCapitalValuationRelative
  48. 48Q-Line Biotech Ltd this pageQLINE · quiet · Too little evidence to rank firmly · 31% evidence59.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.8/43.75 · Revenue — · Profit — · Operating margin change 1 points · 26% evidenceCapital efficiency 24.9/31.25 · ROCE 22.4% (year to Mar 2026) · Operating margin 26.3% · 76% evidenceValuation 13.2/25 · P/E 16.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 21.8 + 24.9 + 13.2 = 59.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  49. 49Bizotic Commercial LtdBIZOTIC · quiet · Too little evidence to rank firmly · 38% evidence59.4out of 100GrowthCapitalValuationRelative
  50. 50Pramara Promotions LtdPRAMARA · Too little evidence to rank firmly · 42% evidence58.6out of 100GrowthCapitalValuationRelative
  51. 51HP Telecom India LtdHPTL · turning · Too little evidence to rank firmly · 43% evidence58.2out of 100GrowthCapitalValuationRelative
  52. 52Aptus Pharma Ltdturning · Too little evidence to rank firmly · 41% evidence55.5out of 100GrowthCapitalValuationRelative
  53. 53Proventus Agrocom LtdPROV · breaking out · Too little evidence to rank firmly · 50% evidence55.1out of 100GrowthCapitalValuationRelative
  54. 54SK Minerals & Additives Ltdquiet · Too little evidence to rank firmly · 45% evidence53.7out of 100GrowthCapitalValuationRelative
  55. 55Monika Alcobev LtdMONIKA · Too little evidence to rank firmly · 22% evidence52.4out of 100GrowthCapitalValuationRelative
  56. 56State Trading Corporation of India LtdSTCINDIA · basing · Too little evidence to rank firmly · 47% evidence50.7out of 100GrowthCapitalValuationRelative
  57. 57AUDROC LtdToo little evidence to rank firmly · 43% evidence47.1out of 100GrowthCapitalValuationRelative
  58. 58Onix Solar Energy LtdONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence46.3out of 100GrowthCapitalValuationRelative
  59. 59Arvaya Healthcare LtdARVAYA · turning · Too little evidence to rank firmly · 46% evidence45.3out of 100GrowthCapitalValuationRelative
  60. 60C K K Retail Mart LtdCKKRETAIL · Too little evidence to rank firmly · 36% evidence45.3out of 100GrowthCapitalValuationRelative
  61. 61Prabhatam Infra Venture Ltdturning · Too little evidence to rank firmly · 27% evidence45.1out of 100GrowthCapitalValuationRelative
  62. 62Satani Bearings Ltdbreaking out · Too little evidence to rank firmly · 43% evidence43.0out of 100GrowthCapitalValuationRelative
  63. 63Keto Motors Ltdquiet · Too little evidence to rank firmly · 43% evidence39.8out of 100GrowthCapitalValuationRelative
  64. 64Aerpace Industries Ltdbreaking out · Too little evidence to rank firmly · 36% evidence38.4out of 100GrowthCapitalValuationRelative
  65. 65RRP Semiconductor LtdRRP · Too little evidence to rank firmly · 47% evidence35.6out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Trading, all 65 compared on one page.

Which companies are close to Q-Line Biotech in size?

Q-Line Biotech is the 21st largest of 61 Trading companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Aerpace Industries, Dhunseri Ventures and Tembo Global Industries. Just below it: Onix Solar Energy, Hexa Tradex and Aptus Pharma.

Trading companies close in size

  1. Aerpace Industries Ltd ₹1,185 crore
  2. Dhunseri Ventures Ltd ₹1,081 crore
  3. Tembo Global Industries Ltd ₹970 crore
  4. Q-Line Biotech Ltd ₹926 crore
  5. Onix Solar Energy Ltd ₹922 crore
  6. Hexa Tradex Ltd ₹845 crore
  7. Aptus Pharma Ltd ₹836 crore

All 61 Trading companies, largest first

Companies close in size in other industries

  1. RSWM Ltd ₹929 crore · Textiles - Spinning
  2. SEPC Ltd ₹929 crore · Project Consultancy/Turnkey
  3. Q-Line Biotech Ltd ₹926 crore
  4. Onida Electronics Ltd ₹924 crore · Consumer Electronics
  5. The Hi-Tech Gears Ltd ₹923 crore · Auto Ancillaries - Gears

What else do people ask about Q-Line Biotech?

What were Q-Line Biotech's latest quarterly results?

Q-Line Biotech Ltd reported revenue of ₹152 Cr and net profit of ₹20.0 Cr for the Sep 2026 quarter. Revenue rose 5.6% and profit fell 4.8% compared with a year earlier. Earnings per share were ₹8.40.

The operating margin was 26.3%, 1.3 percentage points higher than a year earlier (as of 20 November 2026).

What is Q-Line Biotech's market cap?

Q-Line Biotech Ltd's market capitalisation is ₹926 Cr at a share price of ₹396.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).

How is Q-Line Biotech performing?

Q-Line Biotech Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 5.6% and profit fell 4.8% compared with a year earlier.

Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 20 November 2026).

Will Q-Line Biotech's share price go up?

This page does not forecast Q-Line Biotech Ltd's share price. What it shows instead: the share price is ₹396.80, and it has been rising for 22 weeks. Its P/E of 16.9× is higher than 0% of its own last 1 years (as of 20 November 2026).

Who owns Q-Line Biotech?

Promoters own 67.5% of Q-Line Biotech Ltd, foreign institutions 0.9%, domestic institutions 8.2% and the public 23.4% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026).

Does Q-Line Biotech have too much debt?

No, Q-Line Biotech Ltd has little debt: its debt is 0.27× its equity, and its operating profit is 4 times its interest bill. At Sep 2026 borrowings were ₹132 Cr against equity of ₹481 Cr.

So the returns on this page come from the business, not borrowed money (as of 20 November 2026).

Where is Q-Line Biotech in its business cycle?

Q-Line Biotech Ltd's FY26 operating margin was 28.7%, against a 4-year range of 18.6% to 28.7%. The latest quarter was 26.3%, near the top of its own range.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).

What could break the Q-Line Biotech story?

Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).

Is Q-Line Biotech a stock worth studying right now?

What the numbers show: Q-Line Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).

Is there a Q-Line Biotech share price forecast for 2026?

What management itself guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.